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Abstract
A cultivation strategy to increase the productivity of Modified Vaccinia Ankara (MVA) virus in high-cell density processes is
presented. Based on an approach developed in shake flask cultures, this strategy was established in benchtop bioreactors,
comprising the growth of suspension AGE1.CR.pIX cells to high cell densities in a chemically defined medium before infection
with theMVA-CR19 virus strain. First, a perfusion regime was established to optimize the cell growth phase. Second, a fed-batch
regime was chosen for the initial infection phase to facilitate virus uptake and cell-to-cell spreading. Afterwards, a switch to
perfusion enabled the continuous supply of nutrients for the late stages of virus propagation. With maximum infectious titers of
1.0 × 1010 IU/mL, this hybrid fed-batch/perfusion strategy increased product titers by almost one order of magnitude compared to
conventional batch cultivations. Finally, this strategy was also applied to the production of influenza A/PR/8/34 (H1N1) virus
considered for manufacturing of inactivated vaccines. Using the same culture system, a total number of 3.8 × 1010 virions/mL
was achieved. Overall, comparable or even higher cell-specific virus yields and volumetric productivities were obtained using the
same cultivation systems as for the conventional batch cultivations. In addition, most viral particles were found in the culture
supernatant, which can simplify further downstream operations, in particular for MVA viruses. Considering the current avail-
ability of well-described perfusion/cell retention technologies, the present strategy may contribute to the development of new
approaches for viral vaccine production.
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Introduction
Modified Vaccinia Ankara (MVA) virus is a highly attenuated
poxvirus with promising properties as a vectored vaccine.
MVA initiates but cannot complete a full replication cycle in
human recipients and is therefore immunogenic similar to live
virus vaccines (Gomez et al. 2013) but with safety properties
resembling inactivated virus vaccines (Gilbert et al. 2006;
Cebere et al. 2006; Webster et al. 2005; Stickl et al. 1974;
Mayr 2003). MVA recombinants expressing different viral
heterologous antigens have been tested in pre-clinical and
clinical trials as candidate vaccines against infectious diseases
such as AIDS, influenza, severe acute respiratory syndrome
(SARS), and human respiratory syncytial virus (RSV) infec-
tion (Boukhebza et al. 2012; Gilbert 2013; Gomez et al. 2011,
2012). Conventionally, MVA seed virus stocks considered for
vaccine manufacturing are produced in chicken embryo fibro-
blast (CEF) that are fully permissive for MVA. Using well-
established protocols (Altenburg et al. 2014; Cotter et al.
2017), large-scale production of MVA recombinants for im-
munization campaigns would also have to rely on propagation
in CEF (Altenburg et al. 2014). However, because supply with
the primary cell cultures can be challenging for large scale
manufacturing, production of MVA recombinants is being in-
vestigated for continuous suspension cell lines, such as the
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duck cell lines AGE1.CR and AGE1.CR.pIX (Jordan et al.
2009; Lohr et al. 2009), or the duck embryonic stem cell-
derived EB66 cells (Léon et al. 2016).
Influenza viruses are usually processed to provide
inactivated vaccines against seasonal epidemics (Soema
et al. 2015). Production of influenza vaccines in the past
70 years relied on embryonated chicken eggs. Disadvantages
associated with this substrate are the use of an animal-derived
substrate and the potential shortage of eggs especially in case
of a pandemic emergency. Recently, two cell culture-based
vaccines produced either in MDCK cells or in insect cells
using the baculovirus expression vector system were ap-
proved by the FDA (Buckland 2015). In addition, efficient
production of influenza virus has also been shown for other
suspension cell lines including Vero cells (Litwin 1992; Paillet
et al. 2009), PER.C6 cells (Pau et al. 2001), HEK293 cells (Le
Ru et al. 2010), EB66 cells (Brown and Mehtali 2010; White
et al. 2018), and AGE1.CR as well as AGE1.CR.pIX cells
(Jordan et al. 2013; Lohr et al. 2012; Lohr 2014).
Cell culture-derived viral vaccines are typically produced
in biphasic processes. They comprise an initial cell growth
phase and a virus replication phase that initiates with inocula-
tion by seed virus. After the viral genome is amplified and
viral proteins are produced, virions are assembled and proge-
ny virus particles released (Aunins 2000). Typically, cells are
first cultivated in batch mode and infected in the late exponen-
tial growth phase at concentrations in the order of 105–106
cells/mL, with or without a partial exchange of culture medi-
um (Aunins 2000; Tapia et al. 2016). Titers of wild-type MVA
obtained in adherent cultures of CEF cells in serum-containing
medium are in the range of 107–109 infectious units (IU) per
mL (Gilbert et al. 2005; Meiser et al. 2003). The avian cell
lines AGE1.CR.pIX (Jordan et al. 2009; Lohr et al. 2009;
Lohr 2014), EB14 (Guehenneux and Pain 2005) and EB66
(Léon et al. 2016) also yield titers in the order of 108 IU/mL
but with the advantage of enabling suspension cell culture
processes. However, one caveat is that these processes require
induction of suspended cell aggregates for efficient replication
of MVA. A novel MVA derivative, MVA-CR19, was adapted
to propagation in true single-cell suspension cultures without
the requirement for addition of medium to induce cell aggre-
gation (Jordan et al. 2013).
Scalable and intensified processes that yield high titers are
desirable to secure adequate supply with vaccines. In the case
of MVA, high virus titers are required because MVA does not
replicate in human recipients and therefore is not amplified at
the site of injection. Concentrated doses of 108–109 IU/mL are
estimated to be required for clinical applications of MVA
(Gomez et al. 2013; Altenburg et al. 2014). In the case of
influenza vaccines, intensification is desirable because com-
position of multivalent vaccines changes every year, and the
time is short between selection of seasonal virus strains and
desired start of vaccination.
Increasing the concentration of host cells is a standard ap-
proach to intensify production processes for biologicals.
Processes at high cell density (HCD) allow the use of compact
bioreactors with high volumetric production rates and can be
adjusted to viable cell densities of 107–108 per mL (Clincke
et al. 2013). Such cell densities can be achieved in perfusion
mode, which allows for a continuous addition of fresh medi-
um and removal of toxic by-products (such as lactate and
ammonium) while retaining cells in the bioreactor using dif-
ferent retention systems. The production of recombinant pro-
teins in perfusion is typically performed at high-medium ex-
change rates of 1–3media volumes per reactor volume per day
(1/day) or 0.05–0.5 nL/(cell × day) (Konstantinov et al. 2006).
To maintain cultures in a proliferative state at constant high
cell densities, a controlled and continuous removal of cells
from the bioreactor is performed, the so-called Bcell bleed^
(Clincke et al. 2013; Deschênes et al. 2006; Hiller et al. 1993).
Novel cultivation strategies such as n-1 perfusion/high-seed
fed-batch (Yang et al. 2014), concentrated fed-batch (FB)
(Yang et al. 2016), and hybrid perfusion FB (Hiller et al.
2017) have been developed to minimize media use while
maintaining cell-specific and volumetric productivities as well
as guaranteeing consistent product quality.
In the field of viral vaccine production, high cell concen-
trations up to 5 × 107 cells/mL were used for the propagation
of influenza A/PR/8/34 (H1N1) virus (Genzel et al. 2014) and
theMVA-CR19 virus strain (Vazquez-Ramirez et al. 2018). At
those cell concentrations, virus propagation must be per-
formed at optimal pH, temperature, and nutrient concentra-
tions to avoid the so-called Bcell density effect^, a reduction
in cell-specific virus yield often observed for concentrations
exceeding 5 × 106 cells/mL (Lindsay and Betenbaugh 1992;
Maranga et al. 2003).
Several improvements were reported for the HCD produc-
tion of influenza A/PR/8/34 (H1N1) virus. Cultivations were
performed in perfusion cultures for both cell and virus propa-
gation phases using an acoustic filter (Petiot et al. 2011) or an
alternating tangential flow (ATF) system for cell retention
(Genzel et al. 2014). The perfusion systems differed in the
partitioning of the virus. Whereas the acoustic filter allowed
a continuous virus harvest, ATF systems with membrane
pores sizes < 0.5 μm retained most released viral particles in
the bioreactor. In addition, the continuous permeate flow
through the hollow fiber membrane resulted in product losses
due to unspecific binding or membrane fouling by entrapment
of cellular debris and virus particles within the membrane
pores (Genzel et al. 2014). Although cell-specific virus yields
comparable to conventional batch processes were obtained for
both cell retention systems, the volumetric productivity (the
amount of virus per volume of medium spent and time) was
lower (Genzel et al. 2014). This strategy would therefore be
less competitive because of the increased cost of goods
(COGs) for its implementation in large-scale (Pollock et al.
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2013). In an attempt to produce MVA virus (MVA-CR19
strain) at high concentrations in AGE1.CR.pIX cells (5 × 107
cells/mL), perfusion using a medium free of animal-derived
components was implemented (Vazquez-Ramirez et al. 2018).
This method resulted in virus retention and yielded lower cell-
specific and volumetric productivities compared to conven-
tional cell density cultivations. A detailed analysis of several
cultivation strategies in shake flasks demonstrated that a FB
phase followed by a daily medium exchange of 90% can result
in an improvement of both cell-specific yield and volumetric
productivity, even surpassing conventional cell density pro-
cesses performed as a control (Vazquez-Ramirez et al.
2018). While shake flask experiments are essential for the
characterization of production processes, they are insufficient
for establishing strategies for large-scale manufacturing of
vaccines.
Hence, in the present study, an optimized HCD process was
developed in a controlled and scalable cultivation system to
provide the required high yields of MVAvirus. HCD cultures
were achieved in a 1 L bioreactor with an ATF perfusion
system using a manual perfusion control. Perfusion rates were
adjusted applying a fixed cell-specific perfusion rate (CSPR),
which is the volume of medium provided to a single cell per
day (Ozturk 1996). During virus production, the cells were
cultivated in FB followed by a continuous medium exchange
with the same ATF perfusion system used for the cell prolif-
eration phase (hybrid FB/perfusion strategy). Yields and pro-
ductivity of this process confirmed shake flask results. To
investigate options for the use of this strategy to other viral
vaccine production processes, propagation of influenza A vi-
rus was also tested. Again, a similar or even higher productiv-




The AGE1.CR.pIX cell line (here named CR.pIX) is directly
derived from the avian cell line AGE1.CR, which was gener-
ated fromMuscovy duck retina cells (Jordan et al. 2009). The
CR.pIX cells differ from their progenitor AGE1.CR in that
they express the pIX protein of human adenovirus (Jordan
et al. 2009), a virus that is not related to MVA or influenza
viruses. Suspension CR.pIX cells were cultivated in chemical-
ly defined CD-U3 medium (Biochrom GmbH) with a glucose
concentration of 33–40 mM, supplemented with glutamine
(Sigma, Lot SLBS8600) and alanine (Sigma, Lot
BCBS2461V) to a final concentration of 2 mM. In addition,
recombinant insulin-like growth factor (LONG-R3IGF,
Sigma, Lot LOS6008) was added at 10 ng/mL final
concentration. Cells were passaged every 3–4 days at a seed
concentration of 0.8 × 106 cells/mL.
Bioreactor cultivations
CR.pIX cells were inoculated in a 1 L (nominal volume)
benchtop bioreactor (BIOSTAT®B plus, Sartorius AG) at
0.8 × 106 cells/mL in a working volume (Vw) of 0.6–0.8 L
(Table 1). Bioreactors were operated at 37 °C, pH 7.2, and a
stirring speed of 120–160 rpm. Dissolved oxygen concentra-
tion (DO) was controlled at 40% by pulsed aeration with pure
oxygen through a 20-μm pore size micro-sparger unit to a
maximum of 29–38 cm3/min. Cells were initially cultivated
in batch until a glucose concentration of 14–17 mM (60–72 h
after inoculation) was reached. At that point, perfusion was
started using an ATF2 perfusion system controlled by the
C24U-V2.0 controller from Refine Technology and
polysulfone hollow fiber cartridges with pore sizes of
500 kDa (UFP-500-E-4X2MA, GE Healthcare) and
0.65μm (CFP-6-D-4X2MA, GEHealthcare), or polyethersul-
fone hollow fiber cartridges of 0.2 μm (S06-P20U-10-S,
Spectrum Labs) (Table 1). Cell suspension flow rate within
the hollow fiber was set at 1.0 L/min, and defined perfusion
rates were applied to achieve cell densities > 25 × 106 cells/
mL.
Perfusion flow rates during the cell growth phase were
adjusted manually every 12 or 24 h. For that, viable cell den-
sities were measured off-line, and the corresponding flow
rates for that sampling time were calculated to assure a
CSPR of 0.06 nL/(cell × day), which is the optimal exchange
rate for CR.pIX cells based on their glucose consumption rate
(Vazquez-Ramirez et al. 2018). Expected viable cell densities
and the corresponding perfusion flow rates after 12 or 24 h
were calculated taking into account a maximum cell-specific
growth rate of μ = 0.026 h−1 (data not shown). A linear profile
between sampling time points was achieved using the cascade
control of the BIOSTAT®B plus module. Two hours before
infection, one reactor volume was exchanged with fresh me-
dium using the ATF system. A summary of key parameters of
all perfusion cultivations is presented in Table 1.
After medium exchange, bioreactors were infected either
withMVA-CR19 or influenza Avirus A/PR/8/34 (H1N1). For
MVA-CR19 virus, two bolus feeding regimes followed by a
perfusion regime, namely Hybrid 1 (Fig. 1a) and Hybrid 2
(Fig. 1d), were applied to optimize virus propagation at high
cell densities. For Hybrid 1, one-half of the cell suspension
was discarded, and the virus production phase was started
with 0.3 L of cell suspension to allow for a FB with a volume
expansion up to threefold higher than its initial Vw, as de-
scribed before (Vazquez-Ramirez et al. 2018). The FB was
started immediately after virus infection with the addition of
0.15 L of fresh medium to obtain the minimum culture volume
at which the bioreactor impeller was at least 2 cm below the
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medium surface. The FB continued with bolus feedings of
0.15 L at 12 h post infection (hpi) and 0.3 L at 24 hpi.
Finally, perfusion was performed at a rate of one reactor vol-
ume per day 36–120 hpi (Fig. 1a). MVA-CR19 virus particles
(200–400 nm nominal size) were harvested using the same
ATF hollow fiber module (0.65 μm pore size) as in the cell
growth phase.
Similarly, for Hybrid 2, one bolus feed of 0.2 L was done
immediately after virus infection followed by a second feed of
0.25 L at 24 hpi. Subsequently, perfusion was again
performed at a rate of one reactor volume per day 36–
120 hpi (Fig. 1d). In order to improve the virus harvest, the
0.2-μm ATF module used during the cell growth phase was
replaced by a new 0.65-μm module at 36 hpi.
For influenza A virus production, a hybrid strategy
(Fig. 3a) similar to the one assessed for MVA-CR19 virus
was established. Reference processes, one operated complete-
ly in perfusion with total virus retention and one in batch at
conventional cell densities, were performed as proposed pre-
viously by Genzel et al. (2014). A detailed description of the












Perfusion* 800 500 kDa 0.8 0.019 (n = 12, SD = 0.005) 0.026 0.057 (n = 24, SD = 0.006) 247
Hybrid 1 600 0.65 μm 1.0 0.021 (n = 12, SD = 0.006) 0.029 0.068 (n = 18, SD = 0.013) 191
Hybrid 2 600 0.20 μm 8.0 0.024 (n = 4, SD = 0.005) 0.031 0.057 (n = 7, SD = 0.011) 50
Influenza A virus
Perfusion 800 500 kDa 1.0 0.017 (n = 18, SD = 0.011) 0.055 0.072 (n = 24, SD = 0.010) 183
Hybrid 600 0.65 μm 1.0 0.019 (n = 7, SD = 0.004) 0.025 0.119 (n = 20, SD = 0.061)** 168
Batch 800 NA 0.8 0.020 (n = 6, SD = 0.009) 0.033 NA 82
*Vazquez-Ramirez et al. (2018)
**Non-constant CSPR: perfusion rates were automatically adjusted to maintain the pH at a set point of 7.2 and not based on the actual viable cell
densities
***Time from cells inoculation to infection
Fig. 1 Cultivation parameters and cell growth for two hybrid FB/
perfusion variants, Hybrid 1 (a–c) and Hybrid 2 (d–f), for the
production of MVA-CR19 virus at high cell density. a, d Cell-specific
perfusion rate, CSPR, (empty diamonds) and working volume, Vw,
(continuous line). b, e Viable cell density, VCD (squares); on-line
viable cell volume, VCV (continuous line); off-line VCV (full
diamonds) (for VCV calculations see BMaterials and Methods^ section),
and viability (crosses). c, f Glucose (filled circles) and lactate (triangles)
concentration. Time of infection, 0 h (vertical dashed line)
3028 Appl Microbiol Biotechnol (2019) 103:3025–3035
process parameters during cell expansion (Table 1) and per-
formance during virus propagation (Table 2) is presented in
the BResults^ section.
Viruses
All infections withMVA-CR19 virus were carried out with the
working bank no. 22.08.2013 (4.41 × 108 infectious units per
mL (IU/mL)) derived from a virus seed (Jordan et al. 2013)
kindly provided by ProBioGen AG. MVA-CR19 virus seed
aliquots were treated for 1 min in a sonication water bath to
break up virus aggregates, diluted in fresh medium with a
volume equal to 5–6% of the bioreactor Vw, and added to
the cell culture to an MOI (multiplicity of infection) of
0.05 IU/cell.
For all experiments with MVA-CR19 virus, the infectious
titers were determined taking into account its potential appli-
cation as a (live) viral vector (Jordan et al. 2013). Vaccinia
viruses usually replicate in a highly cell-associated fashion.
Therefore, for the quantification of total virus titers (intra-
and extracellular), the cell suspensions were treated for cell
lysis. The lysates were obtained by three freeze/thaw cycles
(− 80°C/RT) followed by 1 min in a sonication water bath
(45 kHz). Cellular debris was removed by centrifugation at
1500×g at room temperature for 10min. For the quantification
of virus released by host cells into supernatant, the samples
were centrifuged at 200×g at RT for 5 min. The cell-free
supernatant was also subjected to three freeze/thaw cycles
before storage (Jordan et al. 2013). All virus samples were
stored in aliquots of 0.5–1 mL at − 80°C. The number of
infectious units was determined as described previously by
Jordan et al. (2009) with a relative standard deviation of ±
0.4 log. The resulting titers are expressed as IU/mL.
The studies with human influenza A virus were performed
with MDCK-derived virus seed A/PR/8/34 H1N1 (Robert
Koch Institute, Amp. 3138) that was adapted to CR.pIX cells
after three passages. The infectious titer of the adapted virus
seed was determined by a TCID50 assay as 1.48 × 10
7 IU/mL.
All bioreactor experiments were performed at an MOI of 1 ×
10−3 in the presence of 1 × 10−6 U trypsin/cell (Gibco, no.
27250–018; prepared in PBS to 500 U/mL) to facilitate prog-
ress of infection. As opposed to MVA, the main application
for influenza virus preparations is inactivated vaccine where
the total concentration of the viral hemagglutinin protein as an
antigen is decisive. For this reason, total virus particle concen-
trations were estimated by a hemagglutination (HA) assay as
previously described by Kalbfuss et al. (2008). HA titers,
expressed as log HA units per test volume (log HAU/
0.1 mL), were converted to virions/mL assuming the binding
of one virus particle per erythrocyte and an erythrocyte con-
centration of 2 × 107 cells/mL, by:
cvirus ¼ 2 107  10 log HAU=0:1 mLð Þ ð1Þ
with cvirus as the total virus concentration in virions/mL. The
relative standard deviation of the method was ± 0.09 log (HA
units/0.1 μL) (Kalbfuss et al. 2008).
The cell-specific virus yield (Yv/cell) was calculated based
on the total (i.e., intra- and extracellular) number of infectious
virus particles (virT, infectivity assay) for MVA virus and on
the total number of all virus particles (cvirus, HA assay) for
influenza A virus, taking into account the total number of
viable cells at the time of sampling (cellT). The latter differed














Perfusion* 800 500 kDa 800 3.2 × 109 13.0 66.4 38 1.0 × 1010
FB + daily harvest (F + D)* 60 NA 95 5.3 × 109 10.0 1.9 270 2.6 × 1011
Hybrid 1 900 0.65 μm 900 1.0 × 1010 10.9 21.9 410 1.3 × 1011
Hybrid 2 750 065 μm 750 1.0 × 1010 8.2 21.3 352 2.8 × 1011
Influenza A virus
Hybrid 810 0.65 μm 810 3.80 × 1010 9.5 23.7 1300 5.43 × 1011
Perfusion 800 500 kDa 800 8.05 × 109 9.6 19.0 340 1.81 × 1011
Batch 800 NA 800 5.23 × 109 8.0 3.1 1344 6.53 × 1011
a For FB-based processes: maximum working volume
b In IU/mL for MVA virus and total virions/mL(estimated from HA measurements) for influenza A virus
c Total time from cell inoculation to maximum titer
d Cell-specific virus yield in IU/cell for MVA virus and total virions/cell (from HA) for influenza A virus
e Volumetric productivity in IU/(L × day) for MVA virus and virions/(L × day) (from HA) for influenza A virus
*Vazquez-Ramirez et al. (2018)
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from the number of viable cells at the time of infection since
cell growth was typically observed up to 36–48 hpi.
Similarly, the volumetric productivity (PV) was calculated
considering virT, the total spent medium during cell growth
and virus replication phase (VT, L), and the total process time
(tT, day), by:
PV ¼ virT= VT  tTð Þ ð2Þ
Determination of cell and metabolite concentrations
Samples of 6–8 mL from bioreactor cultures were taken with a
syringe through a Luer-Lock-septum in 12 or 24-h intervals
and stored at − 80°C until analysis. A validated assay using a
Bioprofile 100 Plus (Nova Biomedical) was used to determine
glucose and lactate concentrations as described previously
(Lohr et al. 2009). Viable cell density (VCD, cells/mL), cell
viability (%), and average cell diameter (μm)were determined
with the cell counter Vi-CELL™ XR (Beckman Coulter)
using a previously validated measuring program with a rela-
tive standard deviation of 2.5% for AGE.CR and CR.pIX cells
(Lohr 2014). Cells analyzed from a total of 100 images were
clustered in diameter classes in the range of 8.1–29.9 μm for
calculation of the total viable cell volume per culture volume
(VCV, μL/mL) using the cell number and cell diameter distri-
bution. For some cultivations, an Incyte® capacitance probe
connected to an Arc View 265 controller (Hamilton Bonaduz
AG) was evaluated for its performance to deliver on-line VCV
data. The on-line system was configured to provide the cell
culture’s permittivity (ε, pF/cm), which correlates directly to
the VCV. On-line permittivity was converted to VCVapplying
a correlation factor VCV/ε of 1.8 obtained from previous cul-
tivations (data not shown).
Results
A strategy previously reported for production of MVA-CR19
virus at high cell densities in shake flasks (Vazquez-Ramirez
et al. 2018) was transferred to a controlled stirred tank biore-
actor with an ATF2 system for cell retention. The method
transfer was investigated for production of MVA and influen-
za A virus.
MVA-CR19 virus propagation using hybrid
FB/perfusion
For the MVA-CR19 virus, this process was adapted for its
implementation in a 0.6-L (Vw) bioreactor. During the cell
growth phase of variant BHybrid 1^, an actual CSPR of
0.068 nL/(cell × day) (Fig. 1a and Table 1) was obtained,
which was comparable to the target 0.06 nL/(cell × day).
This perfusion rate enabled a cell expansion from 1 to >
50 × 106 cells/mL (Fig. 1b) with a μmean of 0.021 1/h
(Table 1). This was comparable to the assumed specific
growth rate of 0.026 1/h for perfusion and was within the
range of 0.016–0.023 1/h from previous reports for batch cul-
tures (Lohr et al. 2012). Manual control of the CSPR during
the cell growth phase also prevented any glucose limitation
and the excessive accumulation of lactate (Fig. 1c).
As an alternative to the Hybrid 1, the Hybrid 2 was started
at 8 × 106 cells/mL and cultivated up to 26 × 106 cells/mL.
The resulting CSPR and μmean were in average 0.057 nL/
(cell × day) and 0.024 1/h, respectively (Table 1). These were
also in accordance with the target values of 0.06 nL/(cell ×
day) and 0.026 1/h. In contrast to the Hybrid 1 cultivation, the
cell suspension was concentrated twofold before infection by
reducing the working volume to 0.3 L (Fig. 1d), and one
reactor volume was exchanged with fresh medium. This pro-
cedure shortened the cell growth phase to 2 days and obviated
discarding half of the volume of the produced cell suspension
(Fig. 1e). Afterwards, the already described hybrid strategy
was applied. The on-line VCV monitoring implemented in
Hybrid 2 correlated well with off-line measurements up to late
stages of the MVA virus propagation phase (Fig. 1e). This
demonstrated the robustness of on-line capacitance measure-
ments when the VCD exceeds 40 × 106 cells/mL, and expand-
ed measurement to stages where virus-induced cell damage
and apoptosis are widely spread within the infected cell pop-
ulation. In general, both the manually controlled CSPR during
the cell growth and the hybrid strategy applied during virus
propagation prevented the glucose limitation and the exces-
sive accumulation of lactate (Fig. 1f).
A maximum MVA-CR19 virus yield of 1.0 × 1010 IU/mL
was obtained at 96 hpi and 72 hpi for Hybrid 1 and Hybrid 2,
respectively (Fig. 2). For Hybrid 1, the virus particles were
harvested using the same ATF hollow fiber module (0.65 μm
pore size) as in the cell growth phase, whereas for Hybrid 2 a
0.2-μm module was used during the cell growth phase and
replaced by a new 0.65-μm module for perfusion and virus
harvest at 36 hpi. The relatively low virus harvest observed in
Hybrid 1 (Fig. 2a) suggested that membrane fouling might
have occurred during the cell growth phase. Nevertheless, a
similar maximum virus titer, cell-specific yield, and volumet-
ric productivity were obtained compared to the reference pro-
cess in shake flasks (Table 2, F + D), which involved daily
harvesting of virus (Vazquez-Ramirez et al. 2018). Even more
significant is the more than tenfold increase in both the cell-
specific yield and the volumetric productivity of Hybrid 1
compared to the use of only perfusion during virus propaga-
tion (Table 2, Perfusion) (Vazquez-Ramirez et al. 2018).
Given the suboptimal virus harvesting for Hybrid 1, the prod-
uct collected in the permeate was not considered for the cal-
culation of the cell-specific yield and the volumetric
productivity.
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For Hybrid 2, almost all infectious virions were found in
the culture supernatant with a maximum virus titer of 1 ×
1010 IU/mL (72 hpi, Fig. 2b). This is in agreement with pre-
vious reports (Jordan et al. 2013; Vazquez-Ramirez et al.
2018). Changing the hollow fiber module during the virus
production phase enabled a quantitative harvest of virus par-
ticles from the supernatant only during the first 12 h of perfu-
sion (i.e., 36–48 hpi) (Fig. 2b). From 48 hpi, the virus particle
concentration in the permeate decreased considerably with
respect to the apparent virus content in the culture supernatant.
The virus titer in the permeate reached 1 × 106 IU/mL at
72 hpi, when the maximum virus titer of 1 × 1010 IU/mL
was reached in the culture supernatant (Fig. 2b). A further
decrease in the permeate virus concentration to 1 × 105 IU/
mL was observed up to 120 hpi, while the titer in the bioreac-
tor remained almost stable in the order of 109 IU/mL (Fig. 2b).
Similar to the Hybrid 1 cultivation, these observations suggest
significant membrane fouling at 48 hpi (24 h after begin of
perfusion), preceding the most productive period of the virus
propagation phase that occurs 48–72 hpi (Fig. 2b). This phase
also coincides with a fast drop of cell viability and, very likely,
with increasing in cell lysis. The resulting massive accumula-
tion of cell debris and the aggregation of MVA-CR19 viral
particles (200–400 nm) may eventually have led to the ob-
struction of the ATF membrane (0.65 μm nominal pore size).
Maximum titers were reached 72 hpi, and infectious virions
appeared to remain stable in the supernatants and as well in the
total cell lysates, as no obvious decay in titers was observed up
to 120 hpi (Fig. 2b).
Despite the differences in the feeding profile during the FB,
the Hybrid 2 variant was as productive as Hybrid 1 (Table 2).
In particular, a cell-specific virus yield of 352 IU/cell and a
volumetric productivity of 2.8 × 1011 IU/(L × day) were ob-
tained. Similar to the Hybrid 1 variant, a very low amount of
product was collected in the permeate line and, therefore, was
neglected for the calculations of the cell-specific yield and the
volumetric productivity. The reduced process time of Hybrid 2
(8.2 days) led to a twofold higher volumetric productivity
compared to cultivation Hybrid 1. However, virus yields in
the order of 1011 IU/(L × day) would still be expected for a
process operated at a similar time period as cultivation Hybrid
1 (10.9 days). As the cell-specific virus yields were compara-
ble to Hybrid 1 (Table 2), the use of both strategies seems
reasonable.
Influenza A virus propagation using hybrid
FB/perfusion
An earlier study that investigated factors interfering with the
production of influenza A virus at HCD gave only partial
solutions regarding productivity optimization (Genzel et al.
2014). Perfusion bioreactors were optimized in this earlier
study with the avian cell line AGE1.CR in such a way that
the cell-specific virus yields increased. However, overall vol-
umetric productivity of these processes was higher in batch
cultivations performed at conventional cell densities. The
AGE1.CR cell line is the parental cell line of CR.pIX cells
and has shown higher productivities for influenza A virus. In
contrast, the productivity was slightly lower for MVA virus
compared to CR.pIX cells (Jordan et al. 2009; Lohr et al.
2009).
Accordingly, it was investigated next whether the hybrid
FB/perfusion strategy established for MVAvirus in this study
could also be used for improving the volumetric productivity
of influenza A/PR/8/34 (H1N1) virus in CR.pIX cells at HCD.
In addition, an alternative perfusion control was evaluated for
the cell growth phase based on the glucose consumption, lac-
tate accumulation, and the resulting medium acidification. To
accomplish this, harvest and medium feeding pumps were
activated when pH dropped to values below 7.2 and turned
off when the pH increased to 7.2. Under this condition, glu-
cose is replenished at the same time that lactate is removed
from the bioreactor. This perfusion control allowed for an
average CSPR of 0.119 nL/(cell × day) (Table 1, Fig. 3a)
and cell viabilities above 92% (Fig. 3b). Additionally, it en-
abled to maintain glucose concentrations above 10 mM (Fig.
3c), similar to a previous report in shake flasks, where the pH
was controlled in a range of 7.2 ± 0.2 when applying a CSPR
of 0.06 L/(cell × day) with fresh CD-U3 medium (Vazquez-
Ramirez et al. 2018). Different to the HIPCOP strategy
Fig. 2 Progression of the MVA-
CR19 virus production for two
hybrid FB/perfusion variants,
Hybrid 1 (a) and Hybrid 2 (b).
Virus titers of whole cell lysates
(filled circles) and permeate
(crosses) are indicated for both
variants. Virus titers in the
supernatant (triangles) were
determined only for Hybrid 2 (b).
Arrows: time points of bolus
feeding
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proposed by Hiller et al. (2017), which operates at glucose
limitation and a lactate consumption regime in CHO cell cul-
tivations, this strategy allowed for a perfusion control without
reaching low glucose concentrations that might negatively
affect the growth of CR.pIX cells.
After the CR.pIX cells were cultivated to 27 × 106 cells/
mL, the Vw was reduced from 0.6 to 0.3 L and 1 reactor
volume was exchanged with fresh medium before virus infec-
tion (Fig. 3a). A final concentration of 47 × 106 cells/mL was
measured just before infection (Fig. 3b). Influenza A viruses
are reported to replicate rapidly in CR.pIX cells (Jordan et al.
2016; Lohr et al. 2009). An increase in HA titers is typically
observed at about 6 hpi and, depending on the virus strain,
maximum titers are obtained 24–36 hpi (Lohr et al. 2009).
Based on this information, and in contrast to the production
ofMVAvirus, the FB phase was shortened (0–12 hpi), follow-
ed by a perfusion phase at a rate of one reactor volume per day
(Fig. 3a). A process operated completely in perfusion and with
total virus retention, as proposed by Genzel et al. (2014), was
performed as a reference process (Online Resource 1).
The hybrid cultivation yielded a maximum HA titer of
3.3 log HAU/100 μL (3.8 × 1010 virions/mL) at 60 hpi
(Fig. 4). This represented a fivefold increase compared to
the reference perfusion cultivation (Fig. 4). Compared to a
conventional batch process (Table 2), the increase was
sevenfold.
Discussion
The implementation of the hybrid strategy in benchtop biore-
actors showed a similar performance compared to analogous
experiments in shake flasks and led to a clear improvement of
virus yields towards perfusion (for HCD) and batch (for con-
ventional cell densities). Next, broader benefits in relation to
reported production strategies with different cell substrates
and its advantages for a potential industrial application were
analyzed.
MVA-CR19 virus propagation using hybrid
FB/perfusion
Although CD-U3 medium was not developed for perfusion
processes (Jordan et al. 2011), medium consumption to
achieve concentrations of about 50 × 106 cells/mL with
CSPR-based perfusion was moderate (6.15 reactor volumes
for Hybrid 1 and 1.98 reactor volumes for Hybrid 2). Despite
the low medium utilization, the average cell-specific growth
rates for both Hybrid 1 and 2 cultivations were comparable to
the 0.023 1/h achieved previously in shake flasks (Vazquez-
Ramirez et al. 2018). Accordingly, it also took only about
8 days to reach a minimum VCD of 50 × 106 cells/mL.
Petiot et al. (2011) reported a medium utilization of about
3.5 reactor volumes to expand HEK293 cells within 9 days
from 0.25 to 15 × 106 cells/mL (before infection with
Fig. 3 Cultivation parameters and cell growth for a hybrid FB/perfusion
process for the poduction of influenza A/PR/8/34 (H1N1) virus at high
cell density. a Cell-specific perfusion rate, CSPR, (empty diamonds) and
working volume, Vw (continuous line). b Viable cell density, VCD
(squares); on-line viable cell volume, VCV (continuous line); off-line
VCV (full diamonds) (for VCV calculations see BMaterials and
Methods^ section), and viability (crosses). c Glucose (filled circles) and
lactate (triangles) concentration. Time of infection, 0 h (vertical dashed
line)
Fig. 4 Progression of influenza A/PR/8/34 (H1N1) virus production for
different cultivation strategies. HA titers and the corresponding total
number of virions/mL are indicated for hybrid FB/perfusion (bioreactor
supernatant: filled circles, permeate: crosses), perfusion (squares), and
batch (triangles)
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influenza virus). Genzel et al. (2014) reported a medium con-
sumption of 11.3 reactor volumes to propagate AGE1.CR
cells to 50 × 106 cells/mL before infection with influenza vi-
rus. Therefore, the results here represent a significant reduc-
tion in medium consumption before virus infection, which is
an important contribution towards lower COGs in large-scale
production.
Both Hybrid 1 andHybrid 2 variants simplify the production
process because a single bioreactor can be used for cell expan-
sion and virus propagation. In Hybrid 1 cultivation, one-half of
the cell suspension (0.3 L) was removed before infection at
50 × 106 cells/mL (Fig. 1 a).This cell suspension could possibly
be used to start a second bioreactor in parallel. In contrast, in the
Hybrid 2 cultivation, cells were cultivated to 25 × 106 cells/mL
in 0.6 L and concentrated to 50 × 106 cells/mL prior to infection
(Fig. 1 d). In both cases, the subsequent FB phase required the
addition of almost three times the starting volume to avoid
substrate limitations. This ratio was lower than the 1:4 reported
by Pohlscheidt et al. (2008) for the high-yield production of
Parapoxvirus ovis at large scale, which—in addition—required
transferring the cell suspension to a second larger bioreactor to
perform the dilution steps. Since the initial FB phase of the
hybrid strategy seems to be a critical operation also for MVA-
CR19 virus propagation (Vazquez-Ramirez et al. 2018), further
studies could focus on the development of an optimized feed
medium to enable a higher starting volume (preferably 60% of
the maximumworking volume) and a lower maximum dilution
ratio (about 2:3) to simplify the hybrid strategy for implemen-
tation in large-scale bioreactors.
Overall, the established hybrid strategies for MVA-CR19
virus production (Table 2, Hybrid 1 and Hybrid 2) resulted in
a 10 to 100-fold increase in virus titers compared to the current
standard production platform in CEF cells (Gilbert et al. 2005;
Meiser et al. 2003). With respect to cultivations performed at
conventional cell densities using CR.pIX cells (Jordan et al.
2009; Lohr et al. 2009; Lohr 2014), EB14 cells (Guehenneux
and Pain 2005), and EB66 cells (Léon et al. 2016), up to tenfold
higher titers were obtained. Cell-specific virus yields obtained
with the hybrid strategies (410 and 352 IU/cell) were also com-
petitive regarding the 500 IU/cell obtained with CEF cells
(Carroll andMoss 1997), the 50–200 IU/cell with CR.pIX cells
(Lohr 2014), and the 25–50 IU/cell with EB66 cells (Léon et al.
2016) at conventional lower cell densities. Batch production of
MVA virus with CR.pIX cells (Jordan et al. 2009; Lohr 2014)
and EB66 cells (Léon et al. 2016) requires more or less the
same time and the same media volumes. Accordingly, its volu-
metric productivity of about 2.0 × 1010 IU/(L × day) is clearly
surpassed by the 1.3 and 2.8 × 1011 IU/(L × day) obtained with
the hybrid strategy. Applying such a strategy would allow for
100,000 doses per liter of cell-free supernatant, considering that
single doses of 1 × 108 PFU (1 PFU = 1 IU) per individual are
currently used in clinical studies involving recombinant MVA-
based vaccines (Gomez et al. 2013).
Due to its application as a viral vector, maintaining the in-
fectious activity of MVA is a critical quality attribute. It is
promising that titers were found to remain stable from 72 to
120 hpi (Fig. 2b). This suggests a low virus inactivation rate for
the specific cultivation conditions chosen. While continuous
virus harvesting failed for the chosen ATF system, the use of
other cell retention devices including acoustic filter and settlers
might be evaluated again for large-scale production to avoid
product losses. One major property of the MVA-CR19 virus,
its capacity to propagate in true single-cell suspension cultures,
may additionally help to facilitate the recovery of infectious
units directly from the culture supernatant without the need of
cell disruption (Jordan et al. 2013). The Hybrid 2 cultivation
showed that the maximum titer at 72 hpi accounted entirely for
virus in the supernatant (Fig. 2b) with most of the cells showing
a viability > 70%. Hence, a clarification step at this point with a
carefully chosen cell retention system would suffice to recover
the MVA-CR19 virus from the bioreactor. Based on the very
high performance of the hybrid strategy in upstream processing
and further options to reduce costs in downstream processing, it
can be assumed that higher costs related to the implementation
of Bcomplex^ perfusion processes (purchase of dedicated
equipment and training of staff) can be more than compensated
even at industrial scale.
Influenza A virus propagation using hybrid
FB/perfusion
The perfusion control applied during the cell growth phase in
the hybrid cultivation led to a μmax = 0.025 1/h and an overall
μmean = 0.019, which were in accordance with previous HCD
bioreactor cultivations (Table 1). Similar to the Hybrid 2 pro-
cess for MVA-CR19 virus, on-line VCVestimations correlat-
ed well with off-line measurements up to late stages of the
influenza A virus propagation phase (Fig. 3b). No glucose
limitation nor significant lactate accumulation was observed
for the pH-based perfusion control during the cell growth
phase (Fig. 3c). The high average CSPR of 0.119 nL/(cell ×
day) (Table 1, Fig. 3a) obtained in the cell growth phase led to
an increase in medium consumption (16.7 reactor volumes)
compared to the reference perfusion process (3.9 reactor vol-
umes). Since the perfusion rates depended on the pH control
of the cultivation, reducing the pH set point could further
minimize the high medium exchange.
Despite the very high medium consumption, the hybrid
strategy provided a cell-specific yield of 1300 virions/cell
and a volumetric productivity of 5.4 × 1011 virions/(L × day)
(Table 2). This observation confirms that the cell density effect
can be circumvented by a hybrid strategy for influenza A
virus-infected cultures. The difference of 17% in volumetric
productivity, with respect to the batch cultivation, can be ex-
plained by the rather high medium consumption during the
cell growth phase of the hybrid cultivation. Compared to the
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perfusion-only strategy, the hybrid FB/perfusion conferred a
clear improvement in both cell-specific and volumetric pro-
ductivity (Table 2), and showed comparable yields for influ-
enza A virus with respect to the parental suspension cell line
AGE1.CR (Genzel et al. 2014).
Process intensification by consequent use of HCD strategies
in viral vaccine manufacturing can contribute to a stable supply
of vaccines. In case conventional batch production processes
are already established, the implementation of HCD strategies
can significantly increase manufacturing capacities, e.g., in
emerging and developing countries where vaccines are most
urgently needed. A possible solution using a hybrid FB/
perfusion strategy during the virus production phase for MVA
and influenza A virus in small stirred tank bioreactors is de-
scribed here. The application of this strategy resulted in a 7-
to 20-fold increase in virus titers without compromising cell-
specific yields and volumetric productivities that often hinder
the establishment of intensified processes. The high titers of
1010 IU/mL obtained for MVA virus demonstrated, in particu-
lar, the potential of this approach as an alternative to the current
technology that relies on primary chicken embryo fibroblasts as
a substrate. The results achieved here for the two different vi-
ruses may be also instructive for modernization of conventional
approaches in viral vaccine production.
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